UY39321A - Combinación de zibotentan y dapagliflozina para el tratamiento de enfermedades relacionadas con endotelina - Google Patents

Combinación de zibotentan y dapagliflozina para el tratamiento de enfermedades relacionadas con endotelina

Info

Publication number
UY39321A
UY39321A UY0001039321A UY39321A UY39321A UY 39321 A UY39321 A UY 39321A UY 0001039321 A UY0001039321 A UY 0001039321A UY 39321 A UY39321 A UY 39321A UY 39321 A UY39321 A UY 39321A
Authority
UY
Uruguay
Prior art keywords
endothelin
zibotentan
treatment
combination
related diseases
Prior art date
Application number
UY0001039321A
Other languages
English (en)
Inventor
Peter Greasley
Ahlström Christine
Stanko Skrtic
Robert Menzies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY39321A publication Critical patent/UY39321A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se refiere al antagonista del receptor de endotelina (ERA) zibotentan en combinación con el inhibidor de cotransportador 2 de glucosa dependiente de sodio (SGLT-2) dapagliflozina para su uso en el tratamiento de ciertas enfermedades relacionadas con endotelina.
UY0001039321A 2020-07-10 2021-07-12 Combinación de zibotentan y dapagliflozina para el tratamiento de enfermedades relacionadas con endotelina UY39321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050147P 2020-07-10 2020-07-10
US202163196793P 2021-06-04 2021-06-04

Publications (1)

Publication Number Publication Date
UY39321A true UY39321A (es) 2022-01-31

Family

ID=76959008

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039321A UY39321A (es) 2020-07-10 2021-07-12 Combinación de zibotentan y dapagliflozina para el tratamiento de enfermedades relacionadas con endotelina

Country Status (17)

Country Link
US (1) US11730735B2 (es)
EP (1) EP4178578A1 (es)
JP (1) JP2023541766A (es)
KR (1) KR20230038234A (es)
CN (1) CN115803028A (es)
AU (2) AU2021305983B2 (es)
BR (1) BR112023000406A2 (es)
CA (1) CA3188345A1 (es)
CL (1) CL2023000097A1 (es)
CR (1) CR20230083A (es)
DO (1) DOP2022000301A (es)
IL (1) IL299568A (es)
MX (1) MX2023000276A (es)
PE (1) PE20230778A1 (es)
TW (1) TW202216147A (es)
UY (1) UY39321A (es)
WO (1) WO2022009163A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202423417A (zh) * 2022-08-12 2024-06-16 瑞典商阿斯特捷利康公司 用於治療肝硬化伴門靜脈高壓之組合療法
US20240307383A1 (en) * 2023-02-08 2024-09-19 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of proteinuria chronic kidney disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP2190433A2 (en) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
EP3019158A1 (en) 2013-07-08 2016-05-18 AbbVie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN110325186A (zh) 2017-02-27 2019-10-11 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与活性成分的组合
CA3083327A1 (en) 2017-11-30 2019-06-06 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
AU2018444285A1 (en) * 2018-10-01 2021-05-20 Astrazeneca Ab Compositions for reducing serum uric acid
KR20230015899A (ko) 2020-04-10 2023-01-31 치누크 세라퓨틱스, 인크. 당뇨병성 신장 질환을 치료하는 방법

Also Published As

Publication number Publication date
WO2022009163A1 (en) 2022-01-13
PE20230778A1 (es) 2023-05-09
US11730735B2 (en) 2023-08-22
CN115803028A (zh) 2023-03-14
TW202216147A (zh) 2022-05-01
JP2023541766A (ja) 2023-10-04
US20220023295A1 (en) 2022-01-27
CR20230083A (es) 2023-05-16
AU2021305983B2 (en) 2024-05-16
KR20230038234A (ko) 2023-03-17
EP4178578A1 (en) 2023-05-17
CL2023000097A1 (es) 2023-09-01
BR112023000406A2 (pt) 2023-01-31
AU2021305983A1 (en) 2023-03-02
MX2023000276A (es) 2023-02-09
IL299568A (en) 2023-02-01
CA3188345A1 (en) 2022-01-13
AU2024204913A1 (en) 2024-08-01
DOP2022000301A (es) 2023-01-31

Similar Documents

Publication Publication Date Title
UY39321A (es) Combinación de zibotentan y dapagliflozina para el tratamiento de enfermedades relacionadas con endotelina
NI201100043A (es) Derivados de dioxa - biciclo [ 3. 2. 1 ] octano - 2, 3, 4 - triol.
AR127030A2 (es) N4-hidroxicitidina y sus derivados y usos antivirales relacionados con la misma
CY1120690T1 (el) Κρυσταλλικη μορφη βενζυλοβενζολικου αναστολεα τουsglt2
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
CO2021009882A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
CO2021009879A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CY1118835T1 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
UY28489A1 (es) Glucopiranosiloxi-pirazoles, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
DE602004028228D1 (de) Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
GT201000037A (es) Depsipéptidos cíclicos
CL2020002011A1 (es) Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer
CL2008002665A1 (es) Composicion farmaceutica compuesta por la fraccion flavonoide purificada micronizada de diosmina y hesperidina y el compuesto dobesilato de calcio; y uso para el control y tratamiento de la insuficiencia venosa cronica.
BRPI0806737A8 (pt) uso de sistema de renomeação de registrador para encaminhar resultados intermediários entre instruções constituintes de uma instrução expandida
RU2009147168A (ru) Новое активное вещество для заживления и его применение
CL2023003893A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcohólica.
CU24717B1 (es) Derivados de azitromicina y roxitromicina como fármacos senolíticos
DE602006013792D1 (de) Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
CO2022013055A2 (es) Tafoxiparina para el tratamiento de la preeclampsia
CO6321268A2 (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e